TP53 and breast cancer: Our data indicated that doxorubicin (125 nM) in combination with RIDR-PI-103 (10 μM) induced p53 phosphorylation at Ser15 in MDA-MB-231 breast cancer cell lines with similar results in MDA-MB-361 and MDA-MB-453 cells.